Abstract
Purpose: In the West, curative (RO) resection is achieved in approximately 50% of patients with localized gastric carcinoma, and more than 60% die of cancer following an RO resection. A multi-institutional study of preoperative chemoradiotherapy was done to assess the RO resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma. Patients and Methods: Operable patients with localized gastric adenocarcinoma were eligible. Staging also included a laparoscopy and endoscopic ultrasonography (EUS). Patients received up to two 28-day cycles of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiation plus concurrent fluorouracil. Patients were then staged and surgery was attempted. Results: Thirty-four patients were registered at three institutions. One ineligible patient was excluded. Most patients had a promixal cancer and EUST3N1 designation. Twenty-eight (85%) of 33 patients underwent surgery. The RO resection rate was 70% and pathCR rate was 30%. A pathologic partial response (< 10% residual carcinoma in the primary) occurred in eight patients (24%). EUS T plus N and postsurgery T plus N correlation showed significant downstaging (P = < .01). The median survival time for 33 patients was 33.7 months. Patients achieving a pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving less than pathPR (12.6 months; P = .03). There were two treatment-related deaths. Conclusion: Our data suggest that the three-step strategy of preoperative induction chemotherapy followed by chemoradiotherapy resulted in substantial pathologic response that resulted in durable survival time. This strategy is worthy of a direct comparison with postoperative adjuvant chemoradiotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 2774-2780 |
Number of pages | 7 |
Journal | Journal of Clinical Oncology |
Volume | 22 |
Issue number | 14 |
DOIs | |
State | Published - 2004 |
ASJC Scopus subject areas
- Oncology
- Cancer Research